Milada Zemanová
- Pulmonary and Respiratory Medicine top 5%
- Oncology top 5%
- Molecular Biology
- Cancer Research top 10%
- Surgery
- Co-authors
- Luboš PetruželkaLibor HavelPetr ZatloukalDalibor Kodrı́kLadislav PecenLibor JudasFilip JankúE Kr̆epela
- Topics
- Lung Cancer Treatments and Mutations (18 papers)Renal cell carcinoma treatment (16 papers)Lung Cancer Research Studies (14 papers)
- Partner nations
- CzechiaUnited StatesPoland
In The Last Decade
Milada Zemanová
61 papers receiving 1.3k citations
Hit Papers
Peers
Comparison fields: 5 of 74
- Pulmonary and Respiratory Medicine 820
- Oncology 590
- Molecular Biology 323
- Cancer Research 213
- Surgery 150
Countries citing papers authored by Milada Zemanová
This map shows the geographic impact of Milada Zemanová's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Milada Zemanová with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Milada Zemanová more than expected).
Fields of papers citing papers by Milada Zemanová
This network shows the impact of papers produced by Milada Zemanová. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Milada Zemanová. The network helps show where Milada Zemanová may publish in the future.
Co-authorship network of co-authors of Milada Zemanová
This figure shows the co-authorship network connecting the top 25 collaborators of Milada Zemanová. A scholar is included among the top collaborators of Milada Zemanová based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Milada Zemanová. Milada Zemanová is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 4 | |
| 3 | 0 | |
| 4 | 11 | |
| 5 | 1 | |
| 6 | 7 | |
| 7 | 2 | |
| 8 | 68 | |
| 9 | 5 | |
| 10 | 5 | |
| 11 | 8 | |
| 12 | 9 | |
| 13 | Circulating tumor cells: what we know, what do we want to know about them and are they ready to be used in clinics? | 13 |
| 14 | 15 | |
| 15 | 5 | |
| 16 | 10 | |
| 17 | 12 | |
| 18 | 2 | |
| 19 | Gemcitabine plus Cisplatin versus Gemcitabine plus Carboplatin in Stage IIIb and IV Non Small Lung Cancer: A phase III Randomized Trial | 41 |
| 20 | 139 |
About Milada Zemanová
Milada Zemanová is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research, having authored 66 papers that have together received 1.3k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (18 papers), Renal cell carcinoma treatment (16 papers) and Lung Cancer Research Studies (14 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (820 citations), Oncology (590 citations) and Cancer Research (213 citations). Milada Zemanová has collaborated with scholars based in Czechia, United States and Poland. Frequent co-authors include Luboš Petruželka, Libor Havel, Petr Zatloukal, Dalibor Kodrı́k, Ladislav Pecen, Libor Judas, Filip Jankú, E Kr̆epela, A Kubík and Pavel Fiala. Their work appears in journals such as Journal of Clinical Oncology, International Journal of Molecular Sciences and Annals of Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.